First Patient Dosed in Phase 1b Trial of VYNE’s BET Inhibitor in Moderate-to-severe PsO

February 20, 2025

Unpacking the New Expert Consensus Panel Recommendations on the Use of Deucravacitinib (Sotyktu, BMS) in Psoriasis

February 11, 2025

Fresh Off the Maui Derm Podium: Guselkumab Shows Significant Skin Clearance in Special PsO Sites

February 6, 2025

Taking on PsO With a New Photopharmaceutical Compound

February 3, 2025

Exploring NF-kB c-Rel’s Role in Psoriasis

February 3, 2025

Health Canada Accepts Arcutis’ SNDS for Roflumilast Foam 0.3% for Scalp and Body PsO

January 22, 2025

Meet the International Psoriasis Council’s Newest Board of Directors and Fellows

January 6, 2025

Deucravacitinib Hits Primary Endpoints in Two Phase 3 PsA Studies

December 23, 2024

U.S. FDA Approves Celltrion’s STELARA Biosimilar

December 18, 2024

Business News: AbbVie to Acquire Nimble Therapeutics and Its Oral Peptide IL23R Inhibitor

December 13, 2024

Ultraprocessed Foods May Up Risk for Psoriasis

November 27, 2024

Mindera Health, NPF Partner to Advance Precision Medicine in Psoriasis

November 19, 2024